微卫星不稳定的癌细胞获得对WRN酶抑制剂的目标耐药性突变
Faith Fowler1, Jessica Gajda2, Amirhossein Mafi1
1Calico Life Sciences South San Francisco, CA United States.
Molecular cancer therapeutics
|February 9, 2026
概括
在微卫星不稳定性 (MSI) 癌症中,对温纳综合征化酶 (WRN) 抑制剂的耐药性迅速出现. 然而,特定突变揭示了开发下一代抑制剂和克服dMMR瘤抵抗力的策略.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药物发现 药物发现 药物发现
背景情况:
- 沃纳综合征基酶 (WRN) 是微卫星不稳定性 (MSI) 癌症的关键标,目前正在进行多项临床试验.
- 获得性耐药性是针对性癌症治疗的一个主要挑战,特别是在具有高突变率的不匹配修复缺陷 (dMMR) 瘤中.
研究的目的:
- 在MSI癌症模型中对WRN抑制剂的耐药性机制的特征.
- 为了确定赋予耐药性的特定突变,并了解它们对抑制剂结合的影响.
主要方法:
- 使用MSI细胞系和异种移植模型,使用临床候选HRO761和两种新型WRN抑制剂.
- 进行全外体序列测序以识别耐药性突变.
- 进行了计算结构分析,以评估突变对抑制剂参与的影响.
主要成果:
- 观察到快速的体外和体内耐药性的出现,与WRN螺旋酶域中的集群突变有关.
- 鉴定了直接阻碍抑制剂结合或改变蛋白质构造的突变.
- 发现了特定的耐药性突变 (L528S,C727R,F730L),显示化学型选择性.
结论:
- 对WRN抑制剂的目标耐药性在dMMR癌症中迅速发展.
- 耐药性概况表明了下一代抑制剂设计和组合治疗策略的机会.
- 这些发现支持继续开发针对MSI癌症的WRN向疗法.
更多相关视频
06:02Live Imaging to Study Microtubule Dynamic Instability in Taxane-resistant Breast Cancers
Published on: February 20, 2017
8.0K
08:59Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
Published on: December 11, 2017
7.6K
相关概念视频
DNA Helicases
24.2K
DNA unwinding helicase enzymes are a type of motor protein. Motor proteins can translocate along filaments or polymers using energy generated from ATP hydrolysis. Helicases are involved in all the important cellular processes where DNA unwinding is required, such as DNA replication, repair, recombination, and transcription. They are present in all living organisms, but vary in their structure, function, and mechanism of action. For example, in prokaryotes, DnaB helicase binds and translocates...
24.2K
Cancers Originate from Somatic Mutations in a Single Cell
15.0K
Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
15.0K
Mutations
94.6K
Overview
94.6K
Treatment Resistant Cancers
3.8K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
Viral Mutations
39.9K
A mutation is a change in the sequence of bases of DNA or RNA in a genome. Some mutations occur during replication of the genome due to errors made by the polymerase enzymes that replicate DNA or RNA. Unlike DNA polymerase, RNA polymerase is prone to errors because it is not capable of “proofreading” its work. Viruses with RNA-based genomes, like HIV, therefore accrue mutations faster than viruses with DNA-based genomes. Because mutation and recombination provide the raw material...
39.9K
Targeted Cancer Therapies
9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.0K
